Nasus Pharma (NSRX) Non-Current Deffered Revenue (2024)
Nasus Pharma (NSRX) posted Non-Current Deffered Revenue of $260000.0 for Q4 2024.
Nasus Pharma (NSRX) Non-Current Deffered Revenue (2024) Analysis & Trends
Nasus Pharma (NSRX) has reported Non-Current Deffered Revenue for 1 consecutive years, with $260000.0 the latest figure, recorded in Q4 2024.
- Non-Current Deffered Revenue for Q4 2024 came in at $260000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $260000.0 (changed N/A YoY), and the FY2024 annual result was $260000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue was $260000.0 for Q4 2024 at Nasus Pharma.
- Over five years, Non-Current Deffered Revenue peaked at $260000.0 in Q4 2024 and troughed at $260000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Nasus Pharma | 28.20 Mn | 23.91 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 260,000.00 |